title: Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.
abstract: After decades of extensive research, epithelial ovarian cancer still remains a lethal disease. Multiple new studies have reported that the immune system plays a critical role in the growth and spread of ovarian carcinoma. This review summarizes the development of dendritic cell (DC) vaccinations specific for ovarian cancer. So far, DC-based vaccines have induced effective antitumor responses in animal models, but only limited results from human clinical trials are available. Although DC-based immunotherapy has proven to be clinically safe and efficient at inducing tumor-specific immune responses, its clear role in the therapy of ovarian cancer still needs to be clarified. The relatively disappointing low-response rates in early clinical trials point to the need for the development of more effective and personalized DC-based anticancer vaccines. This article reviews the basic mechanisms, limitations and future directions of DC-based anti-ovarian cancer vaccine development.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Pennsylvania Health System, Philadelphia, PA, USA.
authors.forename: Janos L
authors.initials: JL
authors.lastname: Tanyi
authors.forename: Christina S
authors.initials: CS
authors.lastname: Chu
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D002277:Carcinoma / Q000276:immunology / Q000628:therapy; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines